Sri Goindwal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.38 M
- Company Age 39 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.59 M
About Sri Goindwal Pharmaceuticals
Sri Goindwal Pharmaceuticals Private Limited (SGPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 December 1985 and has a history of 39 years and one month. Its registered office is in Amritsar, Punjab, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.38 M.
The company has closed loans amounting to ₹1.59 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Prabhjit Singh and Gunit Singh serve as directors at the Company.
Company Details
-
Location
Amritsar, Punjab, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239PB1985PTC006584
-
Company No.
006584
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Dec 1985
-
Date of AGM
08 Jul 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Sri Goindwal Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhjit Singh
|
Director | 27-Jan-2000 | Current |
|
Gunit Singh
|
Director | 18-Dec-1985 | Current |
Financial Performance of Sri Goindwal Pharmaceuticals.
Sri Goindwal Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Goindwal Pharmaceuticals?
In 2017, Sri Goindwal Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹1.59 M
Charges Breakdown by Lending Institutions
- Punjab Financial Corporation : 0.14 Cr
- Punjab National Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 May 1989 | Punjab National Bank | ₹0.20 M | Satisfied |
| 05 May 1988 | Punjab Financial Corporation | ₹1.39 M | Satisfied |
How Many Employees Work at Sri Goindwal Pharmaceuticals?
Unlock and access historical data on people associated with Sri Goindwal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Goindwal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Goindwal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.